(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of -1.25% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Viatris's revenue in 2025 is $14,739,300,000.On average, 3 Wall Street analysts forecast VTRS's revenue for 2025 to be $16,413,561,693,732, with the lowest VTRS revenue forecast at $16,243,716,496,392, and the highest VTRS revenue forecast at $16,580,217,354,735. On average, 3 Wall Street analysts forecast VTRS's revenue for 2026 to be $16,719,035,000,423, with the lowest VTRS revenue forecast at $16,518,264,908,662, and the highest VTRS revenue forecast at $16,919,224,959,451.
In 2027, VTRS is forecast to generate $16,924,627,594,729 in revenue, with the lowest revenue forecast at $16,808,928,119,044 and the highest revenue forecast at $17,112,244,430,164.